Thera-SAbDab

UBLITUXIMAB

>   Structural Summary
TherapeuticUblituximab
TargetMS4A1
Heavy ChainQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS
Light ChainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental TechnologyEMABling Platform
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedLFB Biotechnologies, rEVO Biologics, Johns Hopkins University, TG Therapeutics Inc
Conditions Approvedna
Conditions ActiveChronic lymphocytic leukaemia, Multiple sclerosis, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Non-Hodgkin's lymphoma, Neuromyelitis optica
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]